Targeting of the nuclear prostaglandin receptor peroxisome proliferator-activated receptor ␦ (PPAR␦) by homologous recombination results in placental defects and frequent (>90%) midgestation lethality. Surviving PPAR␦ ؊/؊ mice exhibit a striking reduction in adiposity relative to wild-type levels. This effect is not reproduced in mice harboring an adipose tissue-specific deletion of PPAR␦, and thus likely reflects peripheral PPAR␦ functions in systemic lipid metabolism. Finally, we observe that PPAR␦ is dispensable for polyp formation in the intestine and colon of APC min mice, inconsistent with its recently proposed role in the establishment of colorectal tumors. Together, these observations reveal specific roles for PPAR␦ in embryo development and adipocyte physiology, but not cancer. N uclear hormone receptors are ligand-activated transcription factors that regulate multiple physiological processes, including reproduction, development, energy metabolism, and homeostasis (1). Within the nuclear receptor superfamily, peroxisome proliferator-activated receptors (PPAR) ␣, ␥ and ␦͞␤ comprise a subgroup of three closely homologous genes (2). PPARs have become a major pharmaceutical focus in recent years concomitant with the elucidation of the physiological functions of PPAR␣ and PPAR␥ in lipid homeostasis and energy metabolism (3). PPAR␣, the most clinically relevant mediator of the pharmacological effects of peroxisome proliferators, is a transcription factor dedicated to eliminating excess fatty acids by way of catabolism, including the stimulation of hepatic peroxisomes and fatty acid oxidases (4). PPAR␥ was implicated as a key regulator of adipogenesis (5, 6), as well as in aspects of lipid uptake and efflux in adipocytes and macrophages (7, 8) . These two well-studied PPARs regulate lipid homeostasis by nonoverlapping mechanisms: catabolism vs. mobilization. In addition, PPAR␥ is a high-affinity receptor for the thiazolidinedione class of insulin sensitizers (9, 10), linking lipid metabolism to type II diabetes. The emergence of PPAR␥ as a central differentiation factor in additional cell types, such as the placental trophoblast (6), further broadens the array of physiological and developmental functions controlled by the PPARs.
Targeting of the nuclear prostaglandin receptor peroxisome proliferator-activated receptor ␦ (PPAR␦) by homologous recombination results in placental defects and frequent (>90%) midgestation lethality. Surviving PPAR␦ ؊/؊ mice exhibit a striking reduction in adiposity relative to wild-type levels. This effect is not reproduced in mice harboring an adipose tissue-specific deletion of PPAR␦, and thus likely reflects peripheral PPAR␦ functions in systemic lipid metabolism. Finally, we observe that PPAR␦ is dispensable for polyp formation in the intestine and colon of APC min mice, inconsistent with its recently proposed role in the establishment of colorectal tumors. Together, these observations reveal specific roles for PPAR␦ in embryo development and adipocyte physiology, but not cancer. N uclear hormone receptors are ligand-activated transcription factors that regulate multiple physiological processes, including reproduction, development, energy metabolism, and homeostasis (1) . Within the nuclear receptor superfamily, peroxisome proliferator-activated receptors (PPAR) ␣, ␥ and ␦͞␤ comprise a subgroup of three closely homologous genes (2) . PPARs have become a major pharmaceutical focus in recent years concomitant with the elucidation of the physiological functions of PPAR␣ and PPAR␥ in lipid homeostasis and energy metabolism (3) . PPAR␣, the most clinically relevant mediator of the pharmacological effects of peroxisome proliferators, is a transcription factor dedicated to eliminating excess fatty acids by way of catabolism, including the stimulation of hepatic peroxisomes and fatty acid oxidases (4) . PPAR␥ was implicated as a key regulator of adipogenesis (5, 6) , as well as in aspects of lipid uptake and efflux in adipocytes and macrophages (7, 8) . These two well-studied PPARs regulate lipid homeostasis by nonoverlapping mechanisms: catabolism vs. mobilization. In addition, PPAR␥ is a high-affinity receptor for the thiazolidinedione class of insulin sensitizers (9, 10) , linking lipid metabolism to type II diabetes. The emergence of PPAR␥ as a central differentiation factor in additional cell types, such as the placental trophoblast (6) , further broadens the array of physiological and developmental functions controlled by the PPARs.
Despite a rapid increase in our understanding of PPAR␣ and ␥, the identification of PPAR␦ functions has been lagging behind. Recent studies with a synthetic agonist demonstrated that PPAR␦ can induce reverse cholesterol transport and rectify lipoprotein profiles and triglyceride levels in obese Rhesus monkeys (11) , placing it alongside the remaining PPARs in the regulation of lipid metabolism. More debatable is whether PPAR␦ is a potential regulator of adipocyte differentiation (12, 13) . Apart from metabolism, PPAR␦ was proposed to be a critical mediator of embryo implantation (14) , based on its spatial and temporal expression patterns, and the demonstration that the process requires the naturally occurring PPAR␦ agonists PGI 2 and cPGI (15) . Finally, PPAR␦ was ascribed an oncogenic function after being identified as a direct transcriptional target of ␤-catenin and as a repression target of the nonsteroidal antiinflammatory drug sulindac, a potent suppressor of colorectal tumors (16) . These collective observations implicate PPAR␦ as a versatile regulator of distinct biological processes including, and extending beyond, lipid metabolism.
We report here the generation of a genetic loss-of-function model for PPAR␦, which we use to test existing hypotheses about its function, as well as to identify additional ones. We find that PPAR␦ has an essential role in placentation, such that its deficiency results in frequent embryonic lethality. Surviving PPAR␦ null mice, while rare, are generally healthy and fertile, but display more than a 60% reduction in adipose mass. However, this compromise in adiposity is not recapitulated by an adipocyte-specific knockout of PPAR␦, suggesting that the phenotype is fat-nonautonomous and may evolve from systemic metabolic perturbations. In addition, we report that PPAR␦ is not essential for polyp formation in the gut of APC min mice, although it may have a modest quantitative effect on their growth, reflected in a preferential decrease in the abundance of large polyps in hemizygous and PPAR␦ null animals. These observations refine and add to the previously proposed roles of the receptor, placing PPAR␦ alongside the other PPARs, especially PPAR␥, in regulating versatile processes, such as placentation, fat homeostasis, and colorectal cancer.
Materials and Methods
PPAR␦ Gene Targeting. The exon encoding the N-terminal half of the DNA-binding domain of PPAR␦ was targeted by the CRElox methodology (17) . A loxP sequence was inserted into the upstream intron, while a neo r -TK cassette flanked by two additional loxP sites was introduced into the downstream intron (Fig.  1A) . Southern blot analysis of embryonic stem cells transfected with the targeting allele and selected with G418 revealed frequent homologous integration (Ϸ40%) into the PPAR␦ locus (Fig. 1B) . Two correctly targeted embryonic stem clones were subsequently transfected with a cre-recombinase expressing plasmid (18), followed by negative selection with 1-(2-deoxy-2-fluoro-␤-D-arabinofuranosyl)-5-iodouracil (FIAU) for daughter clones that lost the neo-TK cassette. One of 48 clones screened (arrow in Fig. 1C ) contained cells that had lost the entire segment between the two extreme loxP sites, generating a constitutive loss-of-function allele (PPAR␦ Ϫ ). PCR analysis indicated that this clone also harbored a subpopulation of cells in which only the neo-TK cassette was deleted, yielding a conditional knockout allele, where the two loxP sites flanking the targeted exon are intact, amenable to further CRE-mediated deletion (PPAR␦ ck ; Fig. 1D ). Germ-line chimeras derived from Abbreviations: APC, adenomatous polyposis coli; PPAR, peroxisome proliferator-activated receptor; wt, wild type; E(n), embryonic day; min, multiple intestinal neoplasias. † Present address: The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609. ‡ ‡ To whom reprint requests should be addressed. E-mail: evans@salk.edu.
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this clone transmitted either the PPAR␦ Ϫ or the PPAR␦ ck allele to their progeny, and the two allelic pools were maintained separately thereafter (Fig. 1D) .
Genotyping was performed by using a three-oligonucleotide combination as follows: GAGCCGCCTCTCGCCATCCTT-TCAG (common, 3Ј to the downstream loxP site); GGCGT-GGGGATTTGCCTGCTTCA [wild type (wt)-specific, 5Ј to the downstream loxP site]; and GGCTGGGTCACAAGAGCTAT-TGTCTC (null-specific, 5Ј to the upstream loxP site). Genomic tail DNA is amplified through 35 cycles of: 94°C at 20 s; 60°C at 30 s; 71.5°C at 70 s. Reaction products of Ϸ400, Ϸ360, and Ϸ240 bp represent the PPAR␦ ck , wt, and PPAR␦ Ϫ alleles, respectively.
Induction and Evaluation of Adipocyte-Specific Floxed Allele
Recombination. The generation of aP2-CRE transgenic mice and their characterization will be described elsewhere (W.H., Y.B., J.M.O., and R.M.E., unpublished work). These mice express CRE abundantly in brown and white adipose tissue and only marginally in other tissues, such as skeletal muscle, liver, and heart, as judged by Northern blot analysis and a functional test using R26R-ROSA mice (19) . The aP2-CRE transgene has been introduced into a PPAR␦ ck/ck background, and recombination of the PPAR␦ ck allele was assessed in white and brown adipose tissue, as well as skeletal muscle, by Southern blot analysis (See Fig. 4 ). RNase protection assays to assess the frequency of PPAR␦ mRNA truncation were performed as described (20) , except for the hybridization step, which was carried out by using RPA II hybridization solution (Ambion, Austin, TX).
Intestinal Polyp Analysis. Mice were killed after a 15-h fast, and their guts were flushed with 10% formalin for cleaning and initiating tissue fixation. The colons and intestines were subsequently opened along the mesentery and left in formalin until microscopic evaluation. Specimens were stained by dipping in hematoxylin solution and extensive rinsing with PBS, enhancing the contrast between normal and hyperplastic epithelia. Individual polyps were scored and measured by using a stereo microscope (Leica MZ8), with a calibrated eyepiece. Measurements were performed in a double-blind fashion and sampled by a second observer to avoid bias. Standard deviations in matched cohorts were calculated according to Student's t test.
Histology. Tissue specimens (skin, placenta, polyps) were fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Thin sections were subject to standard hematoxylin and eosin staining. Histological evaluation of intestinal polyps was performed visually by R.B.
Results
Gene Targeting of PPAR␦. We chose a CRE͞lox-mediated recombination strategy to disrupt the PPAR␦ locus ( Fig. 1) . LoxP sites plus a floxed neo-TK cassette were introduced on both sides of the exon encoding the 5Ј half of the DNA-binding domain through homologous recombination. Correctly targeted clones were then transfected with a CRE expression vector (18) and negatively selected against thymidine kinase activity. The procedure yielded two distinct germ-line alleles: a conditional knockout allele (PPAR␦ ck ), which leaves all PPAR␦ exons intact and is amenable to CRE-mediated deletion; and a loss-offunction allele (PPAR␦ Ϫ ), which excised the exon encoding the DNA-binding domain and resulted in a frameshift of the remainder of the mRNA product. These two alleles were maintained independently after germ-line transmission (see Fig. 1D ).
Placental Defects and Frequent Embryonic Lethality in PPAR␦ Null
Mice. Mice homozygous for the PPAR␦ ck allele were obtained from heterozygous crosses at the expected Mendelian frequency (Ϸ25%; data not shown) and exhibited no discernible phenotype. In contrast, homozygous loss of PPAR␦ caused frequent embryonic lethality, as homozygous null pups were rarely obtained (Table 1) . Surviving PPAR␦-deficient progeny were markedly runt at term, but typically overcame growth retardation by puberty, although most were still somewhat smaller than their PPAR␦-sufficient counterparts. None died postnatally, suggesting that the essential function of the receptor is restricted to the gestational period. Both male and female mutants were fertile.
Survival of PPAR␦-deficient mice was relatively even-spread, although not entirely random, and litters with multiple null pups were observed on two different occasions (see Table 1 ). However, subsequent progeny of the same breeding pairs did not similarly exhibit increased survival. In addition, up to six backcrosses of the original knockout stock (129sv͞Jae) against isogenic C57BL͞6J breeders did not improve survival rates (data not shown). These observations fail to establish a clear heritable component influencing the survival of PPAR␦ null mice. Embryonic lethality and sub-Mendelian ratios of PPAR␦ null embryos were observed from embryonic day 10.5 (E10.5) onward (Table 1 ). Mutants surviving beyond that stage were typically smaller than their wt and heterozygous siblings (data not shown). The combination of midterm death and growth restriction pointed to the possibility of defects in extraembryonic tissue. This conjecture was supported by the abundant placental expression of PPAR␦ ( Fig. 2A, lanes 1 and 2) , and the fact that null mouse mortality was strictly prenatal.
Histological examination of PPAR␦ null concepti at E9.5, a day before the onset of lethality, revealed that the connections between their placentas and the maternal deciduas are abnormally loose (arrows in Fig. 2C ; compare with Fig. 2B ). The placental labyrinth, albeit smaller, exhibited a fully differentiated vascular structure, further distinguishing this defect from the one seen in PPAR␥ null placentas. By E10.5, most PPAR␦ Ϫ/Ϫ specimens could not be retrieved without significant detachment of the placenta from the decidua (data not shown), which implies further loosening of the placento-decidual contact upon widening of the gap. By E12.5, three of four PPAR␦ Ϫ/Ϫ embryos surviving the major E10.5 lethality point exhibited extensive maternal hemorrhages into the labyrinthine zone (Fig. 2E, MH) . Finally, a rare PPAR␦ null survivor recovered at E14.5 exhibited an attenuated form of the maternal hematoma, in which the thrombus surrounded, rather than infiltrated the labyrinth (compare Fig. 2 E and F) . The survival of this embryo to E14.5 suggests a link between the severity of the placental phenotype and embryonic lethality.
PPAR␦ Deficiency Decreases Adipose Mass. Examination of surviving PPAR␦ null mice revealed an extremely lean phenotype (Fig.  3 A and B) , typified by a 2.5-fold reduction of abdominal fat mass compared with control littermates (e.g., 1.20 Ϯ 0.29% of carcass weight, n ϭ 4, vs. 3.07 Ϯ 0.33%, n ϭ 3, respectively, in females, P Ͻ 0.0005; see Fig. 4D ). Likewise, the relative mass of interscapular brown fat stores dropped by Ϸ70% (0.1 Ϯ 0.03% in the null vs. 0.29 Ϯ 0.02% in wt, Fig. 4C ; photo not shown). Mesenteric fat, as well as adipose stores associated with internal organs, such as the heart (Fig. 3C, arrow) and kidney, were essentially undeveloped in 4-month-old null animals (Fig. 3D) . Microscopic examination revealed no consistent differences between white or brown adipocytes from mutant vs. wt animals (data not shown), suggesting that reduced adiposity may arise from differences in cell number but not size. In contrast, the subcutaneous fat layer, which was also more than 2-fold thinner in null animals, exhibited a combined decrease in both cell number and size ( Fig. 3 E and F) . Thus, PPAR␦ deficiency affects all adipose types, although the manifestation of the effect is depot-specific.
PPAR␦ expression is ubiquitous and its levels in adipose tissue compare with those elsewhere (Fig. 2 A, lane 8) . Therefore, we wondered whether hypoadiposity of PPAR␦ null mice reflected the loss of an adipocyte function of the receptor or rather a nonautonomous systemic PPAR␦ function. To distinguish between these possibilities, we generated mice carrying two copies of the floxed PPAR␦ ck allele and an adipose-specific CRErecombinase transgene, driven by the promoter of the aP2 gene (aP2-CRE, ref. 21; W.H., Y.B., J.M.O., and R.M.E., unpublished work). Genomic DNA and mRNA analyses showed that aP2-CRE deleted Ϸ50% of PPAR␦ in the gonadal white fat pad, and Ͼ80% of the gene was lost in the interscapular brown fat pad (Fig. 4 A and B) . Recombination was adipocyte-specific, as evidenced by its marginal incidence in skeletal muscle (Fig. 4 A  and B) . Thus, if reduced adiposity was caused by adipocyteintrinsic functions of PPAR␦, its extent in PPAR␦ ck/ck ͞aP2-CRE mice should be proportional to PPAR␦ loss in this tissue. animals revealed no differences between the two cohorts ( Fig. 4 C and D) . This observation was incompatible with an adipocyte-autonomous effect of PPAR␦ on adiposity, suggesting that PPAR␦ controls the process in a systemic fashion. This interpretation ascribes to PPAR␦ a putative function in lipid homeostasis alongside PPAR␣ and ␥.
PPAR␦ Is Dispensable for Colorectal Polyp Formation. PPAR␦ has been recently implicated as a direct target and a potential oncogenic effector of ␤-catenin in colorectal carcinogenesis (16, 22) . To test this hypothesis, we introduced the targeted PPAR␦ allele into the APC min mouse strain. This strain is heterozygous for a mutation in the apc (adenomatous polyposis coli) gene, whose tumor suppressor product inhibits ␤-catenin and its growth-promoting action (23, 24) . Upon loss of heterozygosity for apc in cells of the gastrointestinal mucosa, ␤-catenin activity is deregulated, yielding multiple intestinal neoplasias (min). If PPAR␦ is a critical transducer of the tumorigenic ␤-catenin signal, then its loss should substantially reduce, if not eliminate, intestinal polyps in min mice.
Through an extensive breeding effort we were able to obtain three viable PPAR␦ (Fig. 5C) . Similarly, loss of PPAR␦ did not elicit a statistically significant change in the median size of intestinal polyps (Fig. 5D) . Detailed size distribution analysis revealed a decrease in the abundance of large polyps (Ͼ1.0 mm diameter) upon PPAR␦ gene dosage reduction (Fig. 5E) , which was further pronounced at the largest polyp size category (Ͼ2.0 mm diameter; Fig. 5E ). In contrast, the number of small polyps (Ͻ1.0 mm in diameter) was essentially identical in all PPAR␦ genotype groups. Although below statistical significance in our small cohort, this trend could indicate that polyps with varying degrees of PPAR␦ gene knockout grow slower and are therefore less likely to attain a large size. Thus, PPAR␦ is qualitatively dispensable for the tumorigenic process, although we cannot rule out the possibility that it influences the pace of polyp growth. Discussion PPAR␦ Function During Embryonic Development. We report here that PPAR␦ deficiency is lethal to over 90% of embryos. This observation is similar to an earlier study using a different PPAR␦ targeting configuration (25) , with two critical differences. First, the lethal phenotype of our knockout variant appears to occur earlier during gestation (E10.5 vs. E18.5). Second, in contrast to Peters et al. (25) , we identified neither a heritable component nor a specific genetic background that alleviates this lethality. The difference between the two mutant strains may arise from the different targeting strategies. Whereas our knockout configuration eliminates almost the entire PPAR␦ gene product (see Fig. 1 and Materials and Methods), the one generated by Peters et al. only truncates the C-terminal 60 aa. Conceivably, this limited deletion may fail to abolish PPAR␦ activity in its entirety, because from a structural perspective, the truncated receptor should retain DNA-binding activity, and possibly heterodimerization with retinoid-X receptor. Such residual functions may suffice for increased embryonic survival and a higher proportion of live births.
PPAR␦ has been implicated as a mediator of prostacyclin cPGI and PGI2 functions in embryo implantation (14) . However, the uncompromised fertility of PPAR␦ null females, and the proper Mendelian distribution of PPAR␦ Ϫ/Ϫ postimplantation embryos up to E9.5, do not support this contention. Rather, they unambiguously demonstrate that implantation can proceed in the complete absence of either maternal or embryonic PPAR␦. Thus, either PPAR␦ is not the exclusive molecular target of prostacyclins in this process, or prostacyclins are essential only when the receptor is around. The latter situation is theoretically possible, if unliganded PPAR␦ actively represses implantation, with prostacyclins providing a temporal cue to relieve this inhibition; such derepression would become dispensable if PPAR␦ was missing altogether.
We show here that PPAR␦ is essential for placentation. PPAR␦ Ϫ/Ϫ embryos start dying in parallel to the appearance of an abnormal gap in the placento-decidual interface. Most survivors of the first wave of mortality succumb to subsequent maternal hemorrhages. Conceivably, to survive to parturition, embryos have to evade these structural mishaps to some extent. This seems to be the case with the embryo shown in Fig. 2G , which at E14.5 exhibited a thrombus that had not invaded the placental labyrinth. This phenotypic variant suggests that embryonic survival may reflect an incomplete penetrance of the placental defects.
Placentation is a complex tissue remodeling process, balancing trophoblast invasion and differentiation, decidual response, proteolysis of the extracellular matrix (ECM), and vascular development (26) . The histological appearance of PPAR␦ Ϫ/Ϫ placentas shares striking similarities with those of compound keratin deficiencies (27, 28) . This finding raises the possibility that breakdown of the placento-decidual interface in PPAR␦ null concepti may reflect an imbalance in ECM remodeling, caused by either compromised matrix build-up or excessive proteolysis.
PPAR␦ and Adiposity. The closest homologues of PPAR␦, namely PPAR␣ and PPAR␥, are both established regulators of lipid homeostasis (3). It is therefore reasonable to assume that PPAR␦ should have a related function. This idea is supported in the broadest sense by the ability of PPAR␦ to bind and moderately respond to many of the fatty acids that also activate PPAR␣ and ␥ (2, 15). In addition, PPAR␦ can up-regulate ABCA1 expression and cholesterol efflux in multiple cell types (11) , and the expression of liver fatty-acid binding protein in the gut (29) . Furthermore, administration of a synthetic PPAR␦-selective agonist to primates with adult-onset obesity restores their high density lipoprotein cholesterol levels along with a parallel decrease in plasma triglycerides (11) . In obese-diabetic db͞db mice, PPAR␦ agonists induce a modest increase in total cholesterol and a significant reduction in adipocyte lipoprotein lipase levels (30) . These studies provide compelling evidence that, in the adult, PPAR␦ acts within the context of lipid and lipoprotein metabolism.
In support of this notion, we report here that PPAR␦ null mice display a dramatic reduction in adiposity. This effect is registered uniformly in all types of fat tissue, including gonadal, mesenteric, brown, and subcutaneous stores, all of which exhibit an Ϸ3-fold decrease.
Strikingly, we find that this effect of PPAR␦ deficiency is adipocyte-nonautonomous and cannot be reconstructed by adipocyte-specific PPAR␦ deficiency. Thus, reduced adiposity of PPAR␦ null mice reflects a response of the tissue to an exogenous stimulus, rather than an intrinsic function of the receptor within the fat cell. However, an examination of systemic lipid and lipoprotein profiles did not detect significant changes in the levels of either total cholesterol, high density lipoprotein cholesterol, triglycerides, or free fatty acids in the plasma of fasted PPAR␦ null mice, relative to control littermates (data not shown). These results suggest that PPAR␦ might not impact basal lipid homeostasis, and therefore that its contribution to adiposity is either through an unrelated route, or during active phases of the feeding cycle. PPAR␦ and Colorectal Cancer. PPAR␦ was recently implicated as a direct transcriptional target of ␤-catenin and a critical, sulindacsensitive factor in the development of gastrointestinal neoplasias (16) . This hypothesis was further reinforced by the demonstration that colon cancer cells in which PPAR␦ has been knocked out fail to form tumors in nude mice, where their wt counterparts readily thrive (22) . However, we observe here that PPAR␦ is clearly dispensable for both the formation and elaboration of intestinal and colonic tumors. We did not measure the potential effect of PPAR␦-specific stimuli, such as pharmacological or dietary activation, which may impact tumor progression in the presence of PPAR␦.
While clearly nonessential, PPAR␦ may emerge from our quantitative analysis as a potential modifier of intestinal adenomas. We observed a selective and gradual reduction in the number of larger polyps upon loss of each wt PPAR␦ allele. This trend may provide an indication that PPAR␦ contributes quantitatively toward maximal polyp growth, such that in its absence fewer polyps exceed a diameter of 1 mm.
Conclusion.
We describe here the phenotypic analysis of complete and tissue-specific PPAR␦ null mice. These genetic platforms reveal that PPAR␦ acts at two temporally distinct phases. First, during early development the receptor regulates placentation and is consequently essential for the survival of most embryos. Second, in adult mice it comprises a nonautonomous determinant of adiposity, providing a plausible link to lipid metabolism, and pointing to PPAR␦ as a potential drug target candidate in the treatment of metabolic disorders. Finally, our analyses warrant reassessment of two previously proposed functions of this receptor: embryo implantation and colon cancer. We observe that PPAR␦ is broadly dispensable for both processes. However, we cannot exclude that it may fine-tune these events in conjunction with certain pharmacological or dietary stimuli.
This study fits nicely with the notion that the PPAR family comprises a triad of related receptors controlling lipid homeostasis, among other functions. Intriguingly, placental pathologies further broaden the functional links of PPAR␦ to PPAR␥, which in addition to its established role in adipose tissue, regulates trophoblast differentiation (6). However, unlike PPAR␥ mutants, defects in PPAR␦ null placentas disrupt the placental-decidual interface and do not affect differentiation of the labyrinthine trophoblast, clearly distinguishing between the placental functions of either PPAR. Thus, while conceivably related, PPAR functions are nevertheless nonredundant.
